Stock AnalizDENTSPLY SIRONA Inc. XRAY
Medical/Dental Instruments · IPO 1987 · data as of November 13, 2026
DENTSPLY SIRONA Inc. (XRAY) is a healthcare company listed in the US with a market value of about $1.8B. In the twelve months to September 30, 2026 it had revenue of $3.6B and net income of -$121M, a net margin of -3.4%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is future growth (0/5).
Key numbers: a price to free cash flow of 17.6, 5-year revenue growth of 2% a year, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 50% below the current price.
Score: 1.2 / 5
Checks passed
- P/FCF below 20
- Positive free cash flow
- Pays a dividend
- Share count down over 3 years (buybacks)
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6B | $3.7B | $3.8B | $4.0B | $3.9B | $4.2B | $3.3B | $4.0B | $4.0B | $4.0B | $3.7B |
| Net income | -$121M | -$598M | -$910M | -$132M | -$950M | $411M | -$73M | $256M | -$1.0B | -$1.6B | $430M |
| Free cash flow | $103M | $104M | $281M | $228M | $368M | $515M | $562M | $516M | $317M | $458M | $438M |
| EPS (diluted) | $-0.61 | $-3.00 | $-4.48 | $-0.62 | $-4.41 | $1.87 | $-0.33 | $1.14 | $-4.51 | $-6.76 | $1.94 |
| Net margin | -3.4% | -16.2% | -24.0% | -3.3% | -24.2% | 9.7% | -2.2% | 6.4% | -25.4% | -38.8% | 11.5% |
| ROIC | — | -8.9% | -22.3% | -1.2% | -14.3% | 6.4% | -0.0% | 4.0% | -11.3% | -18.3% | 4.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $11.03, 20% above the current price; targets range from $8.00 to $17.00; the consensus rating is “Hold”; expected EPS is $1.32 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is DENTSPLY SIRONA stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 50% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does DENTSPLY SIRONA pay a dividend?
Not currently.
Is DENTSPLY SIRONA a good stock to buy?
We do not give buy or sell advice. DENTSPLY SIRONA scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.